Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

• Status: NOT_YET_RECRUITING
• Trial end date: 2033-07-31

Summary

• To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML.
• To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.

• Phase: PHASE1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Incyte, Inc
• Treatments: axatilimab; ruxolitinib